Clinical Trial

Pharmacoscopy for Patients With Refractory Primary Brain Tumors

Study acronym: EViDENCE-BT
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level. This personalized therapeutic approach was developed and validated in pre-clinical glioma models. With the current research proposal, we seek to establish feasibility for a clinical interventional trial for patients with refractory primary brain tumors that is based on pharmacoscopy-guided selection of treatment. The study is supported by an unrestricted grant from Anti Cancer Fund.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-27; most recent amendment 2026-04-29.
Status change: Recruiting → Not Yet Recruiting 2025-09-28
Status change: Not Yet Recruiting → Recruiting 2025-09-16
Trial Details
NCT Number NCT06804655
Lead Sponsor University of Zurich
Collaborators: University Hospital, Zürich, University Hospital, Basel, Switzerland, Cantonal Hospital of St. Gallen
Conditions Brain (Nervous System) Cancers, Glioblastoma, Glioma, Ependymoma, Medulloblastoma, Meningioma, Rare Primary Brain Tumors, Rare CNS Primary Tumors
Enrollment 40 participants
Start Date 2026-06-01
Primary Completion 2028-09-15 (estimated)
Study Completion 2028-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-06